In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1723-1727

  Pfaller, Michael A ^a   Messer, S A ^a   Hollis, R J ^a   Jones, R N ^a   Diekemal, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA KRUSEI; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; FUNGAL STRAIN; GEOGRAPHICAL VARIATION (SPECIES); IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; THIAZOLES; TRIAZOLES;

EID: 0036090563     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1723-1727.2002     Document Type: Article

References (29)

1. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
2. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents
3. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent against Aspergillus and Candida
4. In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
5. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
6. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature
7. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
8. In vitro and in vivo activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
9. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis
10. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
11. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients
12. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, SCh 56592, and voriconazole
13. National surveillance of nosocomial bloodstream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
14. National Epidemiology of Mycoses Survey: A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species
15. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program
16. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B
17. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program
18. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans
19. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections
20. Practice guidelines for the treatment of candidiasis
21. Antifungal susceptibility testing: Practical aspects and current challenges
22. In vitro activities of voriconazole (UK-109,496) against fluconazole -susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection
23. Voriconazole: A new triazole antifungal
24. Current and emerging azole antifungal agents
25. Voriconazole
26. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
27. Candida, Cryptococcus, and other yeasts of medical importance
28. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance